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Abstract
Background: We report the interim results from XCiDaBLE, a large, prospective, observational ‘‘naturalistic’’ study evaluating XeominH (incobotulinumtoxinA)
for Cervical Dystonia or BLEpharospasm in the United States.
Methods: Subjects (> 18 years old) with cervical dystonia (CD) are followed for two treatment cycles and monitored via Interactive Voice/Web Response. The
subject’s physician must have chosen to treat with incobotulinumtoxinA prior to and independent of enrollment in this study. Subject-reported scales include the
Subject Global Impression-Severity and Improvement and Cervical Dystonia Impact Profile (CDIP-58), and Work Productivity and Quality of Life (QoL) are
assessed by means of an employment questionnaire and work history and the SF-12v2 Health Survey (SF-12v2). Subjects are seen by the investigator for three visits,
which include a baseline visit (including the first injection), a second injection visit, and a final study visit (12 weeks after the second injection).
Results: This ongoing study includes 145 subjects with a diagnosis of CD. The majority were female (82.3%) and white (91.0%) and had previously been treated
with botulinum toxins (77.2%). There were 106 employed at the time of disease onset, but 12.6 years later only 44% were still employed at the time of enrolment
into the study, and 20% were either receiving or seeking disability benefits. The mean total dose/treatment of CD was 225.2 units for the first injection. The CDIP-
58 total score was significantly improved 4 weeks after the first injection compared to baseline (p#0.0001). Most subjects noted improvement in their global
impression assessment. No new or unexpected adverse events occurred.
Discussion: The results from these interim analyses confirm previous controlled, single-dose studies of incobotulinumtoxinA in terms of efficacy and safety.
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Introduction
Cervical dystonia (CD) and blepharospasm are common forms of
adult-onset focal dystonias. CD is the most common form of focal
dystonia in neurologic clinics, and it is estimated that there are
between 60,000 to 90,000 subjects with this disorder in the United
States.1
Patients with CD experience pain, low self-esteem, embarrassment,
impairment of social interactions, interference with activities of daily
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living, reduced productivity, and employment difficulties.2–4 Several
studies have evaluated the impact of CD on employment and found
that the disorder negatively affected the employment status of 55.3% of
patients.4 Neck pain, specifically, was associated with significantly
altered employment (p,0.0006), reduced productivity (p,0.0001),
and seeking disability benefits (p,0.003).4
The Therapeutics and Technology Assessment Subcommittee of the
American Academy of Neurology recommends botulinum toxin
treatment as an option for patients with CD (based on seven class I
studies; Level A).5 Clostridium botulinum produces seven distinct
serotypes, but only two serotypes (A and B) are commercially available
for clinical use in the United States. All four available botulinum toxin
products are approved by the United States Food and Drug
Administration for use in patients with CD (abobotulinumtoxinA
[DysportH is a registered trademark of Ipsen Biopharmaceuticals,
Inc.], incobotulinumtoxinA [XeominH is a registered trademark of
Merz Pharma GmbH & Co. KGaA], onabotulinumtoxinA [BotoxH is
a registered trademark of Allergan, Inc.], and rimabotulinumtoxinB
[MyoblocH is a registered trademark of Solstice Neurosciences, Inc.]).
Among the four available botulinum toxins, incobotulinumtoxinA
was the most recently introduced in the United States. It received
FDA approval on July 30, 20106 for the treatment of CD and
blepharospasm in adults and on July 21, 2011 for moderate to severe
glabellar lines in adults.7 IncobotulinumtoxinA has demonstrated
efficacy and safety in the treatment of subjects with CD in two Phase
III clinical trials.8–10 Additionally, the long-term safety and effective-
ness of incobotulinumtoxinA in the treatment of CD have been
established in one repeated dose trial.11,12
This prospective, observational study was designed to collect, evaluate,
and report observational data regarding the clinical use of
incobotulinumtoxinA in the ‘‘real-world’’ therapeutic setting (i.e., treating
either CD or blepharospasm using patient-reported outcomes over two
injection cycles). The baseline disease characteristics and results from the
initial 4 weeks following the first injection are described in this paper.
Methods
XCiDaBLE is a multicenter, prospective, observational clinical
study designed to capture ‘‘real-world’’ clinical use and outcomes of
incobotulinumtoxinA treatment in subjects with CD or blepharos-
pasm. The study was initiated in January 2010 and is ongoing at 89
sites in the United States, all of which received Institutional Review
Board/Independent Ethics Committees approval prior to screening
subjects. The study is registered with clinicaltrials.gov (www.
clinicaltrials.gov, identification number: NCT01287247).
Subjects
XCiDaBLE includes subjects with CD who the physician chose to
treat with incobotulinumtoxinA prior to and independent of study
enrollment. All subjects signed and dated written informed consent prior
to study inclusion. As this study was meant to approximate ‘‘real-world’’
clinical practice, there were limited inclusion or exclusion criteria.
However, subjects had to be 18 years or older, could not have been
enrolled in a clinical trial within the past 3 months, and did not have any
contraindications to treatment with incobotulinumtoxinA according to
the United States Prescribing Information for incobotulinumtoxinA.
Randomization
This was a prospective, observational study, and no randomization
was used.
Study drug and injection technique
The selection of incobotulinumtoxinA dosage, dilution, muscles to
be injected, and the use of guidance techniques were at the discretion
of the treating physician. The dose for both injections and the timing
of the second injection were individualized and administered at the
physician’s discretion, but the second injection could not occur less
than 6 weeks after the first injection. The muscles injected for CD
included in this report are: sternocleidomastoid, semispinalis capitis,
longissimus, scalene complex, trapezius, splenius capitis, splenius
cervicis, levator scapulae, and oblique capitis inferior.
Study visits
Subjects were assessed at the baseline visit and, if they met eligibility
criteria, received an injection of incobotulinumtoxinA at that time.
Information regarding the injection was collected and included the
number of muscles injected, dose per muscle, and the dilution ratio of
preserved normal saline to incobotulinumtoxinA. Demographic infor-
mation, as well as disease and employment history, was collected at the
baseline visit prior to injection. Additionally, previous use and outcomes
of prior botulinum toxin treatment or other local or surgical treatments
were collected. Subjects used interactive voice/web response (IVRS/
IVWS) throughout the trial for assessments. IVRS is a technology that
allows the use of a telephone to interact with subjects using a computer-
generated voice that asks questions, and the subject uses the telephone
keypad to respond. Interactive web response system (IWRS) allows
subjects to use a secure website where they can respond to questions by
filling in responses using the computer keyboard. While IVRS and
IWRS are widely used, they have not been specifically validated in
subjects with CD. According to and dependent on clinical practice,
subjects are seen by the investigator for three visits, which include a
baseline visit (including the first injection), a second injection visit, and a
final study visit (12 weeks after the second injection).
Physician-reported outcome measures
Physician Global Impression-Severity (PGI-Severity). PGI-severity was
rated by the treating physician at each injection. The PGI-Severity
measured overall illness severity using a one-item, seven-point Likert
scale (where 15normal, 25borderline, 35mildly, 45moderately,
55markedly, 65severely, and 75extremely).
Subject-reported outcome measures efficacy
Subject Global Impressions (SGI). SGI-Severity was collected at each
injection visit, and SGI-improvement was collected at 4 weeks
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post-injection and the trial endpoint. SGI-Severity measured overall
illness severity using a one-item, 7-point Likert scale (in which
15normal, 25borderline, 35mildly, 45moderately, 55markedly,
65severely, and 75extremely). SGI-Improvement measured global
improvement for the area being treated using a one-item, 7-point
Likert scale (where 15very much improved, 25much improved,
35minimally improved, 45no improvement, 55minimally worse,
65much worse, and 75very much worse).
Cervical Dystonia Impact Profile (CDIP-58). The Cervical Dystonia
Impact Profile (CDIP-58)13–16 was assessed at each injection visit, 4
weeks post-injection, and the trial endpoint. The CDIP-58 is a
validated, disease-specific scale composed of 58 items that fall into
eight subscales (head and neck, pain and discomfort, sleep, upper limb
activities, walking, annoyance, mood and psychosocial function),
which are categorized into three conceptual domains (symptoms,
daily activities, and psychosocial sequelae) to yield a total score. The
CDIP score was transformed to have a common range of 0 (no impact)
to 100 (most impact). The CDIP-58 has been found to be more
sensitive in detecting statistical and clinical changes than comparable
subscales of the SF-36 Health Survey (SF-36), and Toronto Western
Spasmodic Rating Scale (TWSTRS).13
Quality of Life. Quality of life (QoL) was assessed using the SF-12V2H,
which was completed by the subject at each injection and at the end of
the trial. The SF-12V2H Health Survey is a shorter version of the SF-
36H that consists of 12 questions that measure functional health and
well being from the subject’s point of view. Possible SF12v2H scores
range from 0 to 100, with higher scores representing better QoL for
both mental and physical components.17
Work History. Work history was assessed using the validated Work
Productivity and Activity Impairment (WPAI) Questionnaire, which
was completed by the subject on a weekly basis throughout the study.18
The WPAI consists of six questions and is a patient-reported
quantitative assessment of the amount of absenteeism, presenteeism,
and daily activity impairment attributable to general health or a specific
health problem. Each question is evaluated individually; there is no total
score. All visits were assessed to determine potential differences/
fluctuations during the treatment cycle (e.g., peak effect, waning).
Safety
Subjects were asked to report all adverse events (AEs).
Statistical Methodology
Sample Size Determination. Due to the prospective, observational
design of this study, no formal sample size calculation was utilized.
Subject enrollment for both CD and blepharospasm were unrestricted
for a total enrollment of up to 1200 subjects from up to 120 sites. The
initial data for preliminary analysis includes a total of 232 patients with
CD. Only subjects who had a confirmed 4 week post-injection
datapoint for the CDIP were included in the analysis, yielding an
analysis sample size of 145 CD subjects.
Data Analyses. Subject demographic and baseline disease character-
istics; injection patterns and guidance techniques; and efficacy
assessments, including measures of work productivity, QoL, and safety
assessments per injection session are descriptively summarized.
Categorical variables are summarized as counts and percentages using
the number of observations available as the denominator for percent
calculations. Continuous variables are summarized using means and
standard deviation (SD), median, and minimum and maximum values.
No imputation for missing data was performed.
CDIP-58 Analysis. The CDIP-58 score was transformed to have a
common range of 0 (no impact) to 100 (most impact). CDIP-58 score
differences were assessed with the Student’s t-test.
Results
Subjects. As of February 1, 2012, 145 subjects (120 females) who had a
diagnosis of CD have participated in this study. The baseline
demographics and disease characteristics are listed in Table 1. The
mean estimated duration of disease was 12.6 years, the mean age of
disease onset was 43.3 years, and the mean age of the subjects in the
study was 54.9 years. The majority of subjects (77.2%) had previously
received treatment with botulinum toxin, whereas less than a quarter
(22.8%) was toxin-naive. The majority of subjects (75.2%) reported a
positive or partial response to prior treatment with botulinum toxin.
Overall, 73.1% were employed at the time of disease onset, and 44.2%
were employed at the start of the study.
Dosing. Total dose, dilution, muscles injected, and dosing per
individual muscles are summarized in Table 2. The mean total dose
of incobotulinumtoxinA for the first injection was 225.2 U (mean of
159.2 U for toxin-naive subjects; mean of 244.7 U for previously
treated subjects) with a SD of 150.8. Among the toxin-naive subjects,
16 (48.5%) received #120 U of incobotulinumtoxinA, 6 (18.2%)
received 121 to 180 U, and 11 (33.3%) received .180 U. The most
frequent dilution scheme was 1.0 ml of normal saline per 100 U of
incobotulinumtoxinA; however, the range was 1–10 ml per 100 U of
incobotulinumtoxinA. Electromyography (EMG) was used by 58.6%
of injectors for muscle identification, 49.7% used anatomical land-
marks and palpation, and a small proportion used either electrical
stimulation (2.8%) or sonography (0.7%).
Physician-Reported Outcomes
Global Impressions. Physicians rated their global impression of illness
severity (Table 3). According to the investigator rating at baseline, the
majority (81.4%) were quite ill; in fact, investigators rated the subjects
as moderately (49.7%), markedly (24.8%), severely (6.2%), or
extremely ill (0.7%).
Subject-Reported Outcomes
Global Impressions. Subjects rated their global impressions of illness
severity and the improvement following treatment (Table 3).
According to the subject rating at baseline, the majority (64.5%) were
quite ill, and the remaining were rated as moderately (25.4%),
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Table 1. Subject Demographics and Disease Characteristics
N5145






Age (years), mean (SD) 54.9 (12.6)
Age at onset (years), mean (SD) n5140
43.3 (13.7)
Estimated duration of disease (years), mean (SD) n5140
12.6 (9.7)
Age at first botulinum toxin treatment (years), mean (SD) n5112
52.7 (13.0)
Time since most recent botulinum toxin injection (months), mean (SD) n5111
6.7 (15.2)
Number of subjects with previous botulinum toxin therapy, n (%)1 112 (77.2)
Previous botulinum toxin treatments: Serotype and mean number of treatments2
AbobotulinumtoxinA, n (%) 10 (8.9)
Mean (SD) n510
3.0 (1.6)
IncobotulinumtoxinA, n (%) 36 (32.1)
Mean (SD) n536
9.3 (32.8)
OnabotulinumtoxinA, n (%) 100 (89.3)
Mean (SD) n597
13.9 (14.1)
RimabotulinumtoxinB, n (%) 20 (17.9)
Mean (SD) n519
4.1 (3.9)
Effect of previous botulinum toxin treatment
None 3 (2.1)
Partial 38 (26.2)
Fernandez HH, Pagan F, Danisi F, et al. IncobotulinumtoxinA in Subjects with Cervical Dystonia
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services4
markedly (19.6%), severely (15.9%), or extremely ill (3.6%). At 4 weeks
post-injection, 43.1% subjects reported much or very much improve-
ment.
CDIP-58 [For Subjects with CD]. Subjects rated their CD symptoms
using the CDIP-58 (Table 4). The scores have been standardized (with
50 as a mean) for ease of interpretation. The mean total CDIP-58
score was 46.0 at baseline and 36.2 4 weeks after the first injection
(p,0.0001; t-test of change from baseline to Week 4).
SF12v2H and Work Productivity and Activity Impact. Subjects rated
their QoL using the SF12v2H. There were no differences in the mental
or physical QoL at week 4 compared to baseline.
Subjects reported work productivity and activity impact using the
WPAI Questionnaire (Table 5). Among the 138 subjects who
responded at baseline, only 61 were employed. On a scale of 0–10
(05no effect and 105significant effect), subjects rated health affecting
non-work activities as a mean of 5.1 (SD 3.1). Among working subjects,
health affected mean productivity had a mean of 3.4 (SD 2.6). There
were minimal changes seen in every area measured by the WPAI
during the first 4 weeks of treatment.
Safety. Overall, there were only seven subjects who reported any AEs.
Subjects could report more than one AE. There were very few
definitely related or probably related AEs reported, and these included
decreased joint range of motion, musculoskeletal pain, neck pain, and
localized swelling. The majority of definitely related or probably
related AEs were mild to moderate in severity.
Discussion
The typical patient with CD that entered this trial was female, had a
mean age of 55 years, and experienced the onset symptoms of CD at
around 43 years of age. While the majority of subjects were employed
at the time of symptom onset, they were not when they enrolled in this
study. More than two-thirds had previously received injections of
botulinum toxin, with the majority reporting a positive or partial





Previous Botulinum Toxin Duration
Days, Mean (SD) n596
75.9 (27.2)
Baseline Employment
Employed at Time of Onset3 N5145
Yes 106 (73.1)
If Yes to Employed at Onset Was Employment Status Affected4
Different job with less responsibility 5 (4.7)
Loss of employment 20 (18.9)
No 69 (65.1)
Same job, less pay 7 (6.6)
Unknown 5 (4.7)
Receiving or Seeking Disability Benefits?3 N5140
Yes 28 (20.0)
1Subjects may have been on more than one serotype and the total of the n’s are greater than the total number of subjects
2Percentages are based on the number of people who responded to have previous botulinum toxin therapy
3Percentages are based on non-missing values
4The ‘‘n’’ and percentage is based on the number of individuals who responded ‘‘yes’’ or ‘‘no’’ indicating employment. Those who indicated that they are not employed
or those with missing data were excluded from the percentage calculation
Abbreviations: N/n, total subject population/subset of total subject population; %, percentage; SD, standard deviation
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Table 2. Summary of IncobotulinumtoxinA Dosing In Subjects with Cervical Dystonia
Treatment Naive Subjects Pre-Treated Subjects All Subjects
N533 N5112 N5145
Dose at first Injection Visit
Mean (SD) 159.2 (102.5) 244.7 (157.5) 225.2 (150.8)
Volume of Saline/100 U IncobotulinumtoxinA at first
Injection Visit
Range (Min, Max) (1,8) (1,10) (1, 10)
Dosing by Muscle Injection
N5145
Mean (SD)
Sternocleidomastoid n517 n575 n592
37.2 (25.3) 49.7 (56.3) 47.3 (52.1)
Semispinalis Capitis n515 n556 n571
18.0 (8.8) 37.0 (28.3) 33.0 (26.6)
Longissimus n58 n538 n546
20.1 (18.0) 21.9 (17.0) 21.6 (17.0)
Scalene Complex n510 n541 n551
27.7 (27.6) 36.2 (29.6) 34.5 (29.2)
Trapezius n527 n578 n5105
35.0 (21.6) 46.6 (33.9) 43.6 (31.5)
Splenius Capitis n523 n591 n5114
34.3 (34.2) 46.6 (36.7) 44.1 (36.4)
Splenius Cervicals n58 n534 n542
14.5 (8.9) 32.3 (26.1) 28.9 (24.7)
Levator Scapula n519 n567 n586
23.2 (15.7) 34.6 (21.3) 32.1 (20.6)
Oblique Capitis Inferior n55 n511 n516
11.2 (8.0) 28.8 (30.5) 23.3 (26.6)
Summary of Muscle Identification1
Anatomical Location 20 (60.6) 52 (46.4) 72 (49.7)
Electromyography 15 (45.5) 70 (62.5) 85 (58.6)
Electrical Stimulation 1 (3.0) 3 (2.7) 4 (2.8)
Sonography 1 (3.0) 0 (0) 1 (0.7)
1Multiple techniques may have been chosen for an individual subject; therefore, totals do not equal column totals
Abbreviations: N/n, total subject population/subset of total subject population; %, percentage; SD, standard deviation; U, Units
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their physicians. The mean dose of incobotulinumtoxinA for the first
injection of the study was 225.2 U overall (159.2 U among toxin-naive
and 244.7 U among previously treated. It is interesting to note that
among the toxin-naive subjects, 48.5% received #120 U (120 U is the
starting dose according the US Prescribing Information);19 18.2%
received 121 to 180 U and 11 (33.3%) received .180 U.
The four muscles most frequently injected included the splenius
capitis (78.6%), trapezius (72.4%), sternocleidomastoid (63.4%), and
levator scapulae (59.3%), whereas only a minority of injections
targeted the longissimus (30.0%), scalene complex (29.2%), splenius
cervicals (29.0%), and oblique capitis inferior (11.0%). While most
injectors diluted 100 U of incobotulinumtoxinA with 1 cc of normal
saline, the diluent range was 1–10 cc. A small majority (58.6%) of
injectors used EMG for muscle identification, while others used
anatomical location (44.8%), electrical stimulation (2.8%), or sono-
graphy (0.7%).
In this large, prospective, open-label trial, incobotulinumtoxinA
effectiveness was measured by subject-reported outcomes. Most
patients reported improvement 4 weeks post-injection on the subject
global impression scale. Additionally, patients reported statistically
significant improvement on the CDIP-58 (total, conceptual domains,
and subscales). However, not surprisingly, there were no statistically
significant improvements in the QoL measurements (SF12v2 or
Work Productivity and Activity Impact Questionnaire) 4 weeks
post-injection, which is likely due to the short nature of the report.
QoL improvements usually take time. It will be interesting to see if
there are improvements in QoL with consistent individualized
injections over a longer period.
IncobotulinumtoxinA has previously been shown to be a safe and
effective treatment for CD in large trials.8,10 IncobotulinumtoxinA was
studied in two phase 3 trials: one placebo-controlled trial (N5233, with
159 treated with incobotulinumtoxinA)10 and one active-comparator
trial (N5463, with 231 treated with incobotulinumtoxinA).8 The
placebo-controlled trial had a long-term extension in which patients
were re-randomized to either incobotulinumtoxinA 120 U or 240 U.20
All patients could receive up to five treatment cycles with flexibility to
dose as early as the patient needed (but not less than 6 weeks).
Unfortunately, we cannot compare the primary outcome from these
studies with our results because the assessments are different; the
pivotal registration trials utilized the TWSTRS21,22 or the Cervical
Dystonia Severity Scale23 and we utilized the CDIP-58.13
In a study conducted by the authors of the CDIP-58, that
assessment was applied to a clinic-based sample of patients receiving
botulinum toxin A and compared to existing rating scales used in CD,
including two TWSTRS subscales (disability and pain).13 The patients
received questionnaires before and 3 weeks post-botulinum toxin type
A treatment. The results of the CDIP-58 at 3 weeks post-botulinum
toxin type A injection were similar to the results described here. In fact,
Table 3. Global Impressions (Investigator and Subject)
Cervical Dystonia
SEVERITY IMPROVEMENT














Not assessed 0 2 (1.5) Not assessed 1 (0.7)
Normal (1) 5 (3.5) 17 (12.3) Very much Improved (1) 15 (11.0)
Borderline (2) 5 (3.5) 9 (6.5) Much Improved (2) 44 (32.1)
Mildly (3) 17 (11.7) 21 (15.2) Minimally Improved (3) 42 (30.7)
Moderately (4) 72 (49.7) 35 (25.4) No change (4) 21 (15.3)
Markedly (5) 36 (24.8) 27 (19.6) Minimally Worse (5) 6 (4.4)
Severely (6) 9 (6.2) 22 (15.9) Much Worse (6) 6 (4.4)
Extremely (7) 1 (0.7) 5 (3.6) Very much Worse (7) 2 (1.5)
1Percentages are based on non-missing values (N5138)
2Percentages are based on non-missing values (N5137)
Abbreviations: N/n, total subject population/subset of total subject population; %, percentage; SD, standard deviation
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Table 4. Cervical Dystonia Impact Profile (CDIP-58)
Baseline: First Injection Week 4 Post-Injection Treatment Difference
N5137 N5145 n
n n 4 Week – Baseline p-value
Standardized Mean (SD) Standardized Mean (SD) Mean Difference (SD)
TOTAL CDIP-58 n5120 n5119 n5102 ,0.001
46.0 (21.3) 36.2 (21.5) 210.7 (16.5)
CONCEPTUAL
DOMAINS
Symptoms n5129 n5125 n5112 ,0.0001
60.5 (23.2) 47.5 (24.0) 214.3 (20.2)
Daily Activities n5133 n5131 n5122 ,0.0001
39.2 (27.4) 32.5 (25.2) 27.9 (18.6)
Psychosocial Sequelae n5127 n5124 n5111 ,0.0001
41.6 (23.4) 31.7 (22.8) 210.3 (18.1)
SUBSCALES
Head and Neck n5133 n5131 n5121 ,0.0001
64.4 (25.0) 49.2 (24.4) 215.0 (21.1)
Pain and Discomfort n5131 n5127 n5116 ,0.0001
67.4 (28.6) 52.6 (27.9) 215.4 (25.7)
Sleep n5135 n5134 n5126 ,0.0001
46.8 (33.0) 36.5 (31.8) 211.6 (24.8)
Upper Limb Activities n5133 n5134 n5124 0.009
43.5 (27.6) 38.1 (26.8) 26.0 (19.8)
Walking n5135 n5132 n5124 ,0.0001
34.7 (30.7) 26.6 (27.6) 29.4 (22.8)
Annoyance n5134 n5128 n5120 ,0.0001
47.9 (25.6) 35.6 (26.2) 212.9 (21.7)
Mood n5128 n5127 n5115 ,0.0001
36.5 (25.8) 27.1 (23.8) 28.9 (20.7)
Psychosocial Function n5133 n5130 n5121 ,0.0001
40.8 (27.6) 31.2 (25.8) 29.2 (20.1)
The CDIP score was transformed to have a common range of 0 (no impact) to 100 (most impact)
Abbreviations: CDIP, Cervical Dystonia Impact Profile; N/n, total subject population/subset of total subject population; SD, standard deviation
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comparisons of similar subscales among the different measures
revealed that CDIP-58 subscales were more sensitive to statistical
and clinical changes in measuring pain, activities of daily living, and
psychosocial and psychological functioning than the TWSTRS,
functional disability questionnaire, and the medical outcome study
short form-health survey (SF-36) The CDIP-58 was also utilized in a
cross-sectional survey of patients who were being treated with either
onabotulinumtoxinA or abobotulinumtoxinA and were 7–10 weeks
post-injection.24 The subscale scores for the CDIP-58 were similar to
our 4 week post-injection scores, but markedly better (i.e., lower scores)
than our CDIP-58 scores just prior to the first injection. In that study,
the survey was completed by a trained interviewer, and the similar
results suggest that the CDIP-58 can be administered by an interviewer
or via IVRS/IVWS, as in the present study.
No new or unexpected safety issues were uncovered with XCiDaBLE.
IncobotulinumtoxinA was well tolerated in subjects with CD. There
were very few AEs reported. These findings are consistent with the post-
marketing experience with incobotulinumtoxinA. To date, more than
260,000 patients have been exposed to incobotulinumtoxinA worldwide
(based on sales data including samples and exposures during clinical
trials), and there have been no new safety concerns identified by
spontaneous reports during this time period.12
Comparable demographic information has been collected in a
similar study conducted by Allergan, Inc. using onabotulinumtoxinA
(CD PROBE).25 Baseline information for these patients with CD
included: 75.9% female (82.3% in XCiDaBLE), 93.6% Caucasian
(91% in XCiDaBLE), mean age 57.6 years (54.9 in XCiDaBLE), and
symptom onset at 48.3 years (43.3 years in XCiDaBLE). Further-
more, the demographics from both studies are similar to the
incobotulinumtoxinA pivotal study conducted in the United States.10
CD PROBE is slightly different from XCiDaBLE: 1) it includes three
injection cycles of onabotulinumtoxinA compared to two in
XCiDaBLE; 2) CD PROBE has an office visit 4 weeks post-injections
and a telephone interview 6 weeks post-injections, whereas
XCiDaBLE utilizes IVRS/IWRS for systematic evaluations 4 weeks
post-injection; and 3) although both studies utilize CDIP-58, only CD
PROBE conducted TWSTRS at baseline, the third injection, and at
the final visit. Importantly, both studies collect ‘‘naturalistic’’
Table 5. Summary of Work Productivity and Activity Impact Questionnaire
ALL SUBJECTS EMPLOYED SUBJECTS
Currently
Employed



















(Yes) (Range 1–10) (Hours) (Hours) (Hours) (Range 1–10)
n (%) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Baseline
(N5138)
61 (44.2) n5136 n561 n561 n561 n558
5.1 (3.1) 32.3 (13.7) 4.0 (8.4) 2.2 (5.6) 3.4 (2.6)
Week 1
(N5126)
53 (42.1) n5124 n552 n552 n552 n548
4.4 (3.2) 32.5 (15.1) 2.2 (6.6) 1.4 (4.2) 2.8 (2.4)
Week 2
(N5122)
56 (45.9) n5120 n556 n556 n556 n550
4.1 (3.0) 31.1 (15.9) 2.1 (7.0) 1.9 (7.5) 2.8 (2.5)
Week 3
(N5124)
54 (43.6) n5124 n553 n553 n553 n548
4.0 (3.1) 31.8 (15.5) 1.6 (5.9) 1.7 (4.8) 3.1 (2.9)
Week 4
(N5138)
60 (43.5) n5138 n560 n560 n560 n555
3.7 (3.1) 30.4 (14.6) 2.6 (7.3) 2.4 (5.6) 3.0 (2.7)
Note: The productivity and daily activities questions were based on 10-point scales
Abbreviations: N/n, total subject population/subset of total subject population; SD, standard deviation
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information that will help to better understand patients with CD and
their responses to botulinum toxins over time.
Prospective, open-label studies like XCiDaBLE can help physicians
understand the ‘‘real-world’’ use and outcomes of a product; however,
there are limitations to this type of study. The most important is the
lack of a control group. It is interesting to note that the dosing used for
subjects who had been previously treated with botulinum toxins was
slightly higher (245 U) than the dosing used for toxin-naive subjects
(160 U); very few toxin-naive subjects received 120 U in their initial
injection session (mean dose 160 U), which is the current recom-
mended starting dose in the United States Prescribing Information;19
the range of dilution with normal saline was large; and sonographic-
guided injections were rarely used for CD, although this localization
technique is gaining more acceptance, especially in Europe. This
interim data analysis confirms the effect seen in this naturalistic study
as assessed by the CDIP-58 and the statistically significant improve-
ment in this measure observed 4 weeks after an injection of
incobotulinumtoxinA. The magnitude of change in the CDIP-58 is
consistent with other studies that have utilized this assessment.
Moreover, it remains well tolerated when used in a less selective and
wider range of subjects with CD, as compared to the more selective
inclusion of subjects in blinded trials.
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